Kyowa Hakko Kirin

Kyowa Kirin welcomes the decision that NICE will revisit their appraisal of the innovative systemic treatment, POTELIGEO®▼ (mogamulizumab), for adults living with two forms of ultra-rare non-Hodgkin lymphoma

Friday, June 11, 2021 - 1:51pm

Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.

Key Points: 
  • Kyowa Kirin remains committed to finding a solution for people living with SS or MF to have access to POTELIGEO and will continue discussions with NICE and NHS England to find a resolution.
  • We strongly believe in the clinical and cost effectiveness of POTELIGEO and will continue a dialogue with NICE and NHS England.
  • We are hopeful that NICEs reassessment might bring parity with the SMCs decision to make mogamulizumab available in Scotland.
  • You can learn more about the business of Kyowa Kirin at:

MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress

Wednesday, May 12, 2021 - 3:00pm

All presentations will be made available on the EHA website for on-demand viewing on June 11, 2021.\nMEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.

Key Points: 
  • All presentations will be made available on the EHA website for on-demand viewing on June 11, 2021.\nMEI Pharma, Inc. (Nasdaq: MEIP) is a late-stage pharmaceutical company focused on developing potential new therapies for cancer.
  • MEI Pharma\'s portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in an ongoing Phase 2 clinical trial which may support accelerated approval applications with the U.S. Food and Drug Administration.
  • Follow us on Twitter @MEI_Pharma and on LinkedIn .\nKyowa Kirin strives to create and deliver novel medicines with life-changing value.
  • We do not intend to update any of these factors or to publicly announce the results of any revisions to these forward-looking statements.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-to-pr...\n'

Kyowa Kirin Integrates North America Businesses in Support of Company's 2030 Vision and Rapid Growth Trajectory

Wednesday, March 31, 2021 - 9:30pm

BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.

Key Points: 
  • BEDMINSTER, N.J., March 31, 2021 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) a global specialty pharmaceutical company, today announced a key milestone in its North American Business Integration (NABI) initiative; specifically, the merger of its Kyowa Kirin Research and Kyowa Kirin Development companies into Kyowa Kirin, Inc.
  • Kyowa Kirin Canada, Inc. and BioWa, Inc., both maintain their current structure as subsidiaries of Kyowa Kirin, Inc. and Kyowa Kirin USA Holdings, Inc. respectively.
  • The organizational changes we are making through NABI will help Kyowa Kirin North America deliver the full value of these opportunities," says Gary Zieziula, President, Kyowa Kirin North America.
  • You can learn more about Kyowa Kirin North America at: https://kkna.kyowakirin.com.

Cerecor Announces New Worldwide License Agreement with Kyowa Kirin for Anti-LIGHT Antibody CERC-002

Monday, March 29, 2021 - 12:00pm

We are pleased to expand our agreement for this promising first-in-class asset with Kyowa Kirin, a global leader in innovative antibody engineering technology, said Mike Cola, Chief Executive Officer of Cerecor.

Key Points: 
  • We are pleased to expand our agreement for this promising first-in-class asset with Kyowa Kirin, a global leader in innovative antibody engineering technology, said Mike Cola, Chief Executive Officer of Cerecor.
  • Under the terms of the agreement, Cerecor will receive exclusive rights for the development, manufacturing and commercialization of the antibody for all indications worldwide including the United States, Europe and Japan.
  • Kyowa Kirin has an option to retain the rights in Japan.
  • CERC-002 is a fully human anti-LIGHT or tumor necrosis factor superfamily member 14 (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd.

Twist Bioscience and Kyowa Kirin Partner for GPCR Antibody Discovery

Thursday, March 25, 2021 - 12:29pm

Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will leverage its unique Library of Libraries for biologics discovery and its proprietary discovery capabilities to discover novel GPCR target specific antibodies for Kyowa Kirin.

Key Points: 
  • Under the terms of the agreement, Twist Biopharma, a division of Twist Bioscience, will leverage its unique Library of Libraries for biologics discovery and its proprietary discovery capabilities to discover novel GPCR target specific antibodies for Kyowa Kirin.
  • This precise and rational approach to antibody library creation, combined with advanced bioinformatics expertise and automation of the early discovery processes, expedites antibody discovery - decreasing risk, increasing speed, and lowering the failure rate for antibody therapeutic development.
  • Twist received an upfront payment upon signing and Kyowa Kirin retains an option to obtain development and commercial rights to any antibodies resulting from the agreement.
  • That expertise complements Twists unique approach to efficient and robust antibody discovery and optimization, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Harvard University and Kyowa Kirin Enter Strategic Research Alliance

Thursday, February 25, 2021 - 7:00pm

Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) announce that they have entered into a strategic research alliance.

Key Points: 
  • Harvard University and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE:4151) announce that they have entered into a strategic research alliance.
  • Projects selected for funding and scientific collaboration will be identified by a Joint Steering Committee, comprising membership from both Harvard and Kyowa Kirin.
  • Harvard OTDs long-running alliance program creates multi-year, collaborative relationships between the University and corporate partners.
  • In establishing discussions with Kyowa Kirin that led to the creation of this research alliance, OTD was assisted by Gemseki, Inc. , a subsidiary of Shin Nippon Biomedical Laboratories (SNBL), a preclinical CRO in Japan.

A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan

Monday, February 8, 2021 - 1:00am

TOKYO, Feb. 7, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Key Points: 
  • TOKYO, Feb. 7, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).
  • Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.
  • G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014.
  • This investigational product has a function to deliver G-Lasta into the patient's body after a specified time.

A Novel Drug-Device Combination Product Using Terumo's Automated Injection Device Completes Clinical Study in Japan

Monday, February 8, 2021 - 1:00am

TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).

Key Points: 
  • TOKYO, Feb. 8, 2021 /PRNewswire/ -- Terumo Corporation (TSE: 4543) today announced the completion of a clinical study in Japan for a product using Terumo's automated injection device developed in collaboration with Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin).
  • Kyowa Kirin initiated the clinical study in February 2020, to evaluate the safety of the product which combines the drug G-Lasta (generic name: pegfilgrastim (genetical recombination)) and an automated injection device.
  • G-Lasta is a drug for decreasing incidence of febrile neutropenia in patients receiving cancer chemotherapy, launched in Japan by Kyowa Kirin in 2014.
  • This investigational product has a function to deliver G-Lasta into the patient's body after a specified time.

MEI Pharma Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update

Monday, January 4, 2021 - 12:00pm

MEI Pharma also provided an update on pipeline programs and anticipated milestones for 2021 for zandelisib, voruciclib and ME-344.

Key Points: 
  • MEI Pharma also provided an update on pipeline programs and anticipated milestones for 2021 for zandelisib, voruciclib and ME-344.
  • Clinical study costs in the Phase 1b study evaluating the combination are equally shared, and each company is supplying its own investigational agent.
  • MEI and Kyowa Kirin are co-developing and co-promoting zandelisib in the U.S., with MEI booking all revenue from the U.S. sales.
  • In May 2020, updated data from the Phase 1b study of zandelisib was presented at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.

CERC-007: A First in Class Fully Human Anti-LIGHT (TNFSF14) Monoclonal Antibody Licensed from Kyowa Kirin - Emerging Insights and Market Forecast to 2030 - ResearchAndMarkets.com

Wednesday, December 23, 2020 - 5:20pm

"CERC-007- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.

Key Points: 
  • "CERC-007- Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Adult-onset Still's Disease in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
  • CERC-002 is a first in class fully human anti-LIGHT (TNFSF14) monoclonal antibody licensed from Kyowa Kirin Co., Ltd.
    A comprehensive product overview including the product description, mechanism of action, dosage and administration, Research and Development activity.
  • Elaborated details on regulatory milestones and other development activities have been provided in this report.